Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
2.000
+0.130 (6.95%)
At close: Mar 20, 2026, 4:00 PM EDT
1.950
-0.050 (-2.50%)
After-hours: Mar 20, 2026, 7:52 PM EDT
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,595,434
Market Cap
2.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 5 | 0 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2023 | 4 | -16 | -80.00% | 4 | 0 |
| Dec 31, 2022 | 20 | -1 | -4.76% | 16 | 4 |
| Dec 31, 2021 | 21 | 12 | 133.33% | 16 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| BioRestorative Therapies | 11 |
| Purple Biotech | 9 |
| Enveric Biosciences | 6 |
| Galmed Pharmaceuticals | 6 |
| Oragenics | 5 |
| Onconetix | 5 |
ADIL News
- 26 days ago - Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - GlobeNewsWire
- 27 days ago - Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - GlobeNewsWire
- 6 weeks ago - Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 - GlobeNewsWire
- 6 weeks ago - Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 - GlobeNewsWire
- 7 months ago - Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule - GlobeNewsWire